Table of Contents
Pharmaceuticals, Volume 12, Issue 3 (September 2019) – 41 articles
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
- You may sign up for e-mail alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Cover Story (view full-size image) Zika virus (ZIKV) is a mosquito-borne flavivirus that spread throughout the American continent in [...] Read more. Zika virus (ZIKV) is a mosquito-borne flavivirus that spread throughout the American continent in 2015, causing considerable worldwide social and health alarm mainly due to its association with ocular lesions and microcephaly in newborns. Nowadays, no licensed vaccines or antivirals are available against ZIKV, and thus, in this very short time, the scientific community has conducted enormous efforts using different approaches to develop vaccines (inactivated, attenuated, or recombinant) and antivirals (direct-acting and host-targeting), with promising results. It is expected that this huge collaborative effort will produce affordable and effective therapeutic and prophylactic tools to combat ZIKV and other related still-unknown or currently neglected flaviviruses. This article is a comprehensive overview of the advances made in the development of therapeutic measures against ZIKV and the questions that still have to be faced. View this